Lower Respiratory Tract Infections Introduction

References

• Mandell LA, Bartlett JG, Dowell SF et al. Update of Practice Guidelines for the Management of Community- Acquired Pneumonia in Immunocompetent Adults. Clin Infect Dis 2003;37:1405–33.
   Google Scholar
• Niederman MS. Review of treatment guidelines for community- acquired pneumonia. Am J Med. 2004; 117 Suppl 3A: 51S–57S.
   Google Scholar
• File TM. Streptococcus pneumoniae and communityacquired pneumonia: a cause for concern. Am J Med. 2004; 117 Suppl 3A: 39S–50S.
   Google Scholar
• Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J. 2004; 24(1):171–81.
   Google Scholar
• Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998; 113(6): 1542–8.
   Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; 15(2): 167–93.
   Google Scholar
• Cazzola M, Di Perna F, Boveri B et al. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis. J Chemother. 2000; 12(3): 216–22.
   Google Scholar
• Schentag JJ, Strenskosky-Nix LC, Nix DE et al. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis. 1998; 27(1): 40–6.
   Google Scholar
• Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 1999; 14(1): 221–9.
   Google Scholar
• Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998; 279(5): 365–70.
   Google Scholar
• Patel KB, Xuan D, Tessier PR et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother. 1996; 40(10): 2375–9.
   Google Scholar
• Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy. 2000; 20(4): 417–28.
   Google Scholar
• Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000; 46 Suppl 1:6–14.
   Google Scholar
• Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003; 52(4): 616–22.
   Google Scholar
• Soman A, Honeybourne D, Andrews J et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999; 44(6): 835–8.
   Google Scholar
• Meduri GU, Kanangat S, Stefan J, et al. Cytokines IL- 1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria. Am J Respir Crit Care Med. 1999; 160(3): 961–7.
   Google Scholar
• Weiss T, Shalit I, Blau H et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-κB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother. 2004; 48(6): 1974–82.
   Google Scholar
• Mandell LA, Marrie TJ, Grossman RF et al. Summary of Canadian guidelines for the initial management of community- acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J. 2000; 7(5): 371–82.
   Google Scholar
• Mandell LA, Bartlett JG., Dowell SF et al. Update of Practice Guidelines for the Management of Community- Acquired Pneumonia in Immunocompetent Adults. Clin Infect Dis 2003;37:1405–33.
   Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4): 243–50.
   Google Scholar
• BTS Pneumonia Guidelines Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56 (suppl IV):1–6
   Google Scholar
• Lim WS, Van Der Erden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5): 377–82.
   Google Scholar
• Balter MS, La Forge J, Low DE et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003; 10 Suppl B: 3B–32B.
   Google Scholar
• Ball P, Vaquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002; 49(1): 31–40.
   Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6): 932–46.
   Google Scholar
• Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999; 116(1): 40–6.
   Google Scholar
• Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Pulmonary Perspectives 2002; 19(1) :1–8.
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163(7): 1730–54.
   Google Scholar
• Landen H, Moller M, Tillotson GS et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res. 2001; 29(2): 51–60.
   Google Scholar
• Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest. 1998; 113(4 Suppl): 249S–255S.
   Google Scholar
• Morris S, Sutton M, Gravelle H. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use. PharmacoEconomics, 2002, Vol: 20: 153–16
   Google Scholar
• Miravitlles M, Murio C, Guerrero T et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121(5): 1449–55.
   Google Scholar
• Lucioni C, Donner CF, De Benedetto F, et al. I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD). PharmacoEconomics - Italian Research Articles. 2005; 7 (2): 119–134.
   Google Scholar
• Grassi C, Casali L, Curti E et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 2002; 14(6): 597–608.
   Google Scholar
• Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004; 125(3): 953–64.
   Google Scholar
• Sessa A, Seminara N, Bettoncelli G et al. Lo studio Aquarius: criteri di ospedalizzazione delle polmoniti acquisite in comunità. Società Italiana di Medicina Generale. 2004; 3: 10–14.
   Google Scholar
• Mazzaglia G, Caputi AP, Rossi A et al. Exploring patient and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary care. Eur J Clin Pharmacol (2003) 59: 651–657.
   Google Scholar
• Dye C, Scheele S, Dolin P et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999 ; 282(7): 677–86.
   Google Scholar
• Phillips MS, von Reyn CF. Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis. 2001; 33(8): 1363–74.
   Google Scholar
• Brown-Elliott BA, Wallace RJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002; 15(4): 716–46.
   Google Scholar
• Zanetti S, Ardito T, Sechi M et al. Evaluation of a nonradiometric system (BACTEC 9000 MB) for detection of mycobacteria in human clinical samples. J Clin Microbiol, 1997; 35(8):2072–5.
   Google Scholar
• Sanguinetti M. Routine Use of PCR-Reverse Cross-Blot Hybridization Assay for rapid identification of mycobacterium species growing in liquid media. J Clin Microbiol, 1998;1530–1533.
   Google Scholar
• Tenover F, Crawford JT, Huebner RE et al. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol, 1993: 767–770.
   Google Scholar
• Global Tuberculosis Control. WHO Report 2003. WHO/HTM/TB/2004.331
   Google Scholar
• Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004; 169(10):1103–9.
   Google Scholar
• Gosling R, Gillespie S. Moxifloxacin treatment of tuberculosis. Antimicrob Agents Chemother. 2004; 48(9):3642.
   Google Scholar
• De Benedetto M, Belussi L, Cassano P et al. Consensus report on the diagnosis of rhino-bronchial syndrome (RBS). Acta Otorhinolaryngol Ital. 2003; 23(5): 406–8.
   Google Scholar
• Coyle AJ, Gutierrez-Ramos JC. The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol. 2004; 25(3–4): 349–59.
   Google Scholar
• Ikeda K, Tanno N, Tamura G et al. Endoscopic sinus surgery improves pulmonary function in patients with asthma associated with chronic sinusitis. Ann Otol Rhinol Laryngol. 1999; 108(4): 355–9.
   Google Scholar
• ATS. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med, 1996;153(5):1711–25.
   Google Scholar
• Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115(2): 462–74.
   Google Scholar
• Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997; 278(23): 2080–4.
   Google Scholar
• Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001; 119(2 Suppl): 397S–404S.
   Google Scholar
• Weinstein RA. Nosocomial infection update. Emerg Infect Dis. 1998; 4(3): 416–20.
   Google Scholar
• Destache CJ. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999; 43 Suppl A: 107–13.
   Google Scholar
• Lorenz J, Busch W, Thate-Waschke IM et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res. 2001; 29(2): 74–86.
   Google Scholar